Patent intelligence · US
US 9682033
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
Patent details — US 9682033
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 20, 2017
- Expiration
- Jun 15, 2037
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Claims
- 22
- CPC classes
- A61K, A61K31/167, A61K31/407, A61K31/4439
Quick answer
US 9682033 (Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted Jun 20, 2017. Expires Jun 15, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/167, A61K31/407, A61K31/4439, A61K31/5517, A61K47/10
More from TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 9682033?
US 9682033 (Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted Jun 20, 2017. Expires Jun 15, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9682033?
TEVA PHARMACEUTICALS INTERNATIONAL GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 9682033 expire?
Our index shows an expiration date of Jun 15, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.